| For: | Singh MM, Shah A, Rajak S, Chaturvedi CP, Sinha RA. Histone lactylation: A key epigenetic modulator in the pathogenesis of metabolic dysfunction-associated steatohepatitis and alcoholic steatohepatitis. World J Hepatol 2025; 17(12): 111153 [PMID: 41479511 DOI: 10.4254/wjh.v17.i12.111153] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i12/111153.htm |
| Number | Citing Articles |
| 1 |
Kaibo Sun, Yuangang Wu, Yuan Liu, Peiting Ma, Bin Shen, Huiqi Xie. Biomaterials for metabolic reprogramming in skeletal disorders. Chinese Medical Journal 2026; doi: 10.1097/CM9.0000000000004285
|
| 2 |
Jieyan Wang, Zhou Li, Xiya Li, Xiyu Liu, Zhaohua Zhong, Yantong Wan, Hui Liang. Mapping the intellectual landscape of lactylation research: a bibliometric analysis of global trends and emerging frontiers. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1841236
|
| 3 |
Ya-qi Guo, Dan-jie Li, Chen-xi Jia, Pan-pan Hou, Chun-jie Yang, Yu-ting Xi, Xing Liu, Peng Li, Chang-zheng Li, Qian-qian Niu. Lactylation in metabolic dysfunction-associated steatotic liver disease: epigenetic regulatory mechanisms and potential therapeutic strategies. Biochemical Pharmacology 2026; 251 doi: 10.1016/j.bcp.2026.118193
|
| 4 |
Li Zhu, Bo Wu. Revisiting macrophage metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease: mechanisms, regulation, and therapeutic breakthroughs. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1899587
|
| 5 |
Zhiwei Dong, Feibo Xu, Mei Ye, Lu Wang. Lactylation in liver fibrosis: from molecular mechanisms to targeted therapeutic strategies. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1930280
|
| 6 |
Yi Sun. Macrophages in MASLD: from inflammatory and metabolic crosstalk to exercise intervention. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1894884
|